Challenges of measuring accurate estradiol levels in aromatase inhibitor‐treated postmenopausal breast cancer patients on vaginal estrogen therapy

Breast cancer patients who are taking adjuvant Aromatase Inhibitor (AI) therapy typically have extremely low estradiol levels, which are undetectable by routine clinical laboratories. Thus, it becomes difficult to assess the safety of interventions such as low‐dose vaginal estrogen, which may increa...

Descripción completa

Detalles Bibliográficos
Autores principales: Niravath, Polly, Bhat, Raksha, Al‐Ameri, Mohamed, AlRawi, Ahmed, Foreman, Claudette, Trivedi, Meghana V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5684855/
https://www.ncbi.nlm.nih.gov/pubmed/28805983
http://dx.doi.org/10.1002/prp2.330

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5684855/
https://www.ncbi.nlm.nih.gov/pubmed/28805983
http://dx.doi.org/10.1002/prp2.330

Ejemplares similares